Short answer
Arcutis Biotherapeutics, Inc. (ARQT) filed its Q3 2025 10-Q quarterly report on Oct 28, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $99M (up 121.7% year over year) with net income of $7M.
Q3 2025 key financials · XBRL
- Revenue
- $99M
- +121.7% YoY · +21.7% QoQ
- Net income
- $7M
- +117.8% YoY · +146.6% QoQ
- Operating margin
- 8.6%
- EPS (diluted)
- $0.06
- +118.2% YoY · +150.0% QoQ
Source: XBRL data from the Arcutis Biotherapeutics, Inc. (ARQT) Q3 2025 10-Q on SEC EDGAR. USD.
Arcutis Biotherapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New regulatory risk from One Big Beautiful Bill Act (Jul 2025) cutting Medicaid spending by $1 trillion, potentially lowering life sciences revenue
- Most material update: tax law changes including possible increased U.S. tax expense and one-time charges affecting deferred tax asset values
- OECD/G20 global minimum tax rules (15% rate) enacted in some jurisdictions, limited expected impact as U.S. adoption remains uncertain
- Operational risk: uncertainty in state conformity with federal tax laws impacting tax planning and financial performance
- Financial risk: potential increased future U.S. tax expense and cash flow effects due to evolving tax legislation and reforms
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Arcutis Biotherapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.